EGFR and neoplasm: Previous studies on ICD have mostly focused on factors with the potential to improve tumor immunogenicity and antigen presentation, including cellular stressors; conventional chemotherapeutic drugs, such as cyclophosphamide, oxaliplatin, and docetaxel [34,35]; tyrosine kinase inhibitors, such as crizotinib [36]; the epidermal growth factor receptor (EGFR) specific monoclonal antibody cetuximab [37]; oncolytic virotherapy [38,39,40]; epigenetic modifiers; and numerous physical interventions [41,42,43,44].